FC001
Pre-clinical- Indications
- Periprosthetic joint infection
Company intelligence / Profile preview
ForCast Orthopedics is developing a proprietary, automated targeted antibiotic delivery platform designed to treat periprosthetic joint infections by delivering high concentrations of antibiotics directly to the site of infection. Their lead program, FC001, has received both Orphan Drug Designation and Qualified Infectious Disease Product (QIDP) status from the FDA. The approach aims to improve outcomes over current standard-of-care treatments by effectively targeting bacterial biofilms that are resistant to systemic antibiotics. Early-stage grants and recognitions support proof-of-concept efficacy models; no published late-stage clinical results yet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ForCast Orthopedics.